Theravance Biopharma (TBPH) Tax Provisions (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Tax Provisions of -$1.5 million for Q1 2026, down 168.34% year-over-year from $2.2 million in Q1 2025, and down 106.37% quarter-over-quarter from $23.6 million in Q4 2025.
Theravance Biopharma (TBPH) Tax Provisions (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Tax Provisions for 13 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 168.34% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at $33.9 million (up 239.88% YoY), while the FY2025 annual figure was $34.9 million, up 195.42% from the prior year.
- Tax Provisions slipped to -$1.5 million in Q1 2026 per TBPH's latest filing, from $23.6 million in the prior quarter.
- Across five years, Tax Provisions topped out at $23.6 million in Q4 2025 and bottomed at -$6.5 million in Q3 2025.
- Historically, Tax Provisions has averaged $2.8 million across 5 years, with a median of $524000.0 in 2022.
- Annual changes were most pronounced in 2022 — Tax Provisions slumped 7142.86% — and 2023, when it jumped 29260.0%.
- Theravance Biopharma's Tax Provisions stood at -$3000.0 in 2022, then jumped by 9666.67% to $287000.0 in 2023, then jumped by 2195.47% to $6.6 million in 2024, then jumped by 257.67% to $23.6 million in 2025, then sank by 106.37% to -$1.5 million in 2026.
- Business Quant data shows TBPH's Tax Provisions at -$1.5 million in Q1 2026, $23.6 million in Q4 2025, and -$6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Mar 31, 2026 | -1.50 Mn |
| Dec 31, 2025 | 23.56 Mn |
| Sep 30, 2025 | -6.50 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Mar 31, 2025 | -559,000.00 |
| Dec 31, 2024 | 6.59 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | 287,000.00 |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | -395,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | -507,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 524,000.00 |
| Dec 31, 2021 | -200,000.00 |
| Sep 30, 2021 | -7,000.00 |